Bristol Myers Squibb’s stock surged dramatically after pharmaceutical giant AbbVie announced disappointing results in its recent clinical trials for a promising schizophrenia drug. The development has positioned Bristol Myers Squibb as a stronger player in the highly competitive and lucrative schizophrenia treatment market, as AbbVie’s setback gives Bristol Myers Squibb an unexpected advantage. AbbVie recently […]
AbbVie, the renowned American biopharmaceutical giant, is set to acquire Aliada Therapeutics for a staggering $1.4 billion. The acquisition grants AbbVie control over Aliada’s promising Alzheimer’s treatment, ALIA-1758, and the biotech’s innovative Modular Delivery (MODEL) platform, which could overcome significant barriers in treating neurological disorders, particularly Alzheimer’s disease. Key Drivers Behind the Acquisition AbbVie aims […]
NImmune Biopharma has entered into a strategic partnership with BioTherapeutics, a clinical-stage biotech company based in Virginia, to accelerate the development of next-generation precision medicines targeting inflammatory and autoimmune diseases. This collaboration is poised to leverage BioTherapeutics’ advanced computational modeling, regulatory expertise, and unique animal models to fast-track NImmune Biopharma’s pipeline, particularly its LANCL immunoregulatory […]
AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY (epcoritamab), a groundbreaking therapy for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) following two or more prior treatments. This approval marks a significant milestone as TEPKINLY becomes the first and only […]
In a significant move within the biotechnology industry, AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company, has completed the acquisition of Celsius Therapeutics, Inc., a pioneer in the development of therapies for inflammatory diseases. This acquisition, valued at $250 million in cash, underscores AbbVie’s strategic commitment to expanding its immunology portfolio by incorporating Celsius’ promising […]
The U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor developed by AbbVie, for the treatment of adults with moderately to severely active ulcerative colitis. This marks a significant milestone as SKYRIZI becomes the first IL-23 specific inhibitor approved for this condition, in addition to its approval for moderate to […]
In a significant development in the pharmaceutical industry, AbbVie Inc. (NYSE: ABBV) and FutureGen Biopharmaceutical (Beijing) Co., Ltd. have entered into a licensing agreement to progress FG-M701, an advanced TL1A antibody aimed at revolutionizing the treatment of inflammatory bowel disease (IBD). The collaboration, valued at approximately $1.71 billion including milestones and royalties, marks a pivotal […]
AbbVie Inc. (NYSE: ABBV) has announced encouraging findings from an interim analysis of a 156-week extension study, assessing the long-term safety and effectiveness of atogepant, an oral medication designed for migraine prevention. Conducted over three years, this Phase 3, open-label study involves participants with chronic or episodic migraine. According to the data, atogepant continues to […]
AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food and Drug Administration (FDA) granting full approval for ELAHERE (mirvetuximab soravtansine-gynx), marking a major advancement for patients suffering from this challenging condition. ELAHERE is designed to treat folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or […]
Zydus Worldwide DMCC, a wholly-owned subsidiary of Zydus Lifesciences Ltd., and South Korea’s Daewoong Pharmaceutical Co., Ltd. have entered into a significant exclusive licensing agreement. This collaboration aims to co-develop and commercialize Leuprolide Acetate for Depot Suspension (reference listed drug: Lupron Depot, AbbVie) in six dosage strengths for the United States market. Shared Responsibilities and […]
